. 2019 May 23;137(8):867–876. doi: 10.1001/jamaophthalmol.2019.1318

Table 3. Genome-Wide Significant and Suggestive Lead Variants Associated With Geographic Atrophy Lesion Growth.

Variant^a	Chr	Position (hg19)	Reference Allele	Alternative Allele	Alternative Allele Frequency				Slope per Allele (95% CI)^b		P Value	95% of Credible Set^c	99% of Credible Set^c
Variant^a	Chr	Position (hg19)	Reference Allele	Alternative Allele	AREDS	FAM/ DSGA	GATE	All	Root Transformed, mm/y	Inverse Normal Transformed	P Value	95% of Credible Set^c	99% of Credible Set^c
rs11184959	1	107 213 976	G	A	0.375	0.340	0.338	0.352	0.046 (0.026- 0.066)	0.246 (0.155- 0.338)	4.09 × 10⁻⁸	24	37
rs2839127	21	47 573 550	G	A	0.115	0.159	0.174	0.145	0.059 (0.034- 0.085)	0.346 (0.221- 0.471)	1.0109 × 10⁻⁸	1	1
rs145146260^d	11	90 194 708	CT	C	0.079	0.046	0.096	0.070	0.105 (0.068- 0.143)	0.441 (0.270- 0.612)	4.0709 × 10⁻⁷	32	47

Abbreviations: AREDS, Age-Related Eye Disease Study; Chr, chromosome; DSGA, Directional Spread in Geographic Atrophy; FAM, Fundus Autofluorescence Imaging in Age-Related Macular Degeneration; GATE, Geographic Atrophy Treatment Evaluation.

^{^a}

Per dbSNP.

^{^b}

Adjusted for the number of geographic atrophy lesions, follow-up time, presence of bilateral geographic atrophy, and the first 2 principal components of ancestry.

^{^c}

Number of variants in the 95% or 99% credible set of association, containing the true variant with 95% or 99% probability, respectively.

^{^d}

Suggestive evidence for association (P < 1.00 × 10⁻⁶).